Our FDA GRAS approved flagship strain: Bacillus coagulans SNZ 1969™ is unique in the space of spore forming probiotic strains. It boasts an exceptional history of use, stability profile, research and genetic pedigree. Combined with Sanzyme’s experience in end-to-end production and decades of continuous technological improvement, SNZ 1969™ is a reliable, long term choice for inclusion in probiotic formulations in supplements, food, and pharmaceuticals.
Pedigree
- The technology for the production of SNZ 1969 and the mother culture was transferred via technology transfer by Sankyo Japan in 1972
- Strain was isolated from green malt and is a sister strain to the original Nakamura strain
End to End Production in a Dedicated Facility
- Sanzyme Biologics manages all inputs, and process parameters at all stages of probiotic production: from flasks to seed fermenters to full scale fermentation to blending and spray drying.
- Due to our years of experience in production of Bacillus coagulans, Sanzyme has made constant incremental improvements to the inputs used and production. The result is a healthier spore, and we test this against our stringent assay method.
Proven Stability in a
variety of dosage forms
Clinical References
- Clinical trial of Sporlac in gastroenteritis. 1999
Ronald Ross Institute of Tropical Diseases, Hyderabad. - Randomised controlled clinical trial of Lactobacillus sporogenes (Bacillus coagulans), used as probiotic in clinical practice, on acute watery diarrhea in children. Dutta P et al., Tropical Medicine and International Health 2011; volume 16 no 5, pp 555– 561.
- Effect of Lactobacillus on the incidence and severity of acute rotavirus diarrhea in infants. A prospective placebo-controlled double blind study Chandra R.K., Nutrition Research 2002; 22: 65–69
- Sporlac in neonatal diarrhea – Dhongade R. K. and Anjaneyulu R., Maharashtra Medical Journal 1977; XXIII (II): 473
- Effect of Lactobacillus on the incidence and severity of acute rotavirus diarrhea in infants. A prospective placebo-controlled double- blind study Chandra R.K., Nutrition Research 2002; 22: 65–69
- Sporlac in neonatal diarrhea – Dhongade R. K. and Anjaneyulu R., Maharashtra Medical Journal 1977; XXIII (II): 473
- A Study showing antagonistic effect of Lactobacilli casei and Lactobacilli sporogenesis against some common pathogens- in vitro. Shukla P. and Sharma J., Int. J. Curr. Microbiol. App. Sci 2015; 4(6): 36-40
- A study on the antibiotic susceptibilities of some probiotic strains used as the dietary supplements. Sharma J. and Shukla P., International Journal of Institutional Pharmacy and Life Sciences 2015; 5(5): September-October
- Immunomodulatory activity of Lactobacillus sporogenes. BABAR V., THOMAS R., BHASKAR M., International Journal of Therapeutic Applications 2012; Volume 3: 32 – 38
- Evaluating antimicrobial activity of common commercial Probiotic Products against Staphylococcus aureus – Sharma J. and Goyal A., Indian Res. J. Genet. & Biotech 2017; 9(2) May: 272 – 278
- A Study showing antagonistic effect of Lactobacilli casei and Lactobacilli sporogenesis against some common pathogens- in vitro.
Shukla P. and Sharma J., Int. J. Curr. Microbiol. App. Sci 2015; 4(6): 36-40 - Clinical trial of Sporlac in the treatment of recurrent Apthous ulceration Sharma J. K. et al., U.P. State Dental Journal 1980; Vol 11 January: 7-12
- A comparative evaluation of probiotics on salivary mutans streptococci counts in Indian children Jindal G et al., European Archives of Paediatric Dentistry 2011; 12: Issue 4
- Preliminary observations on effect of Lactobacillus sporogenes on serum lipid levels in hypercholerolemic patients Mohan J. C. et al., Indian J Med Res (B) 1990; Vol 92 December: 431-432.
Know more about Bacillus Coagulans SNZ1969, its use and other questions visit @https://www.sanzymebiologics.com/
